anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A therapeutic composition may include a fluid component and/or a matrix component derived from amnion. A matrix component may be an amniotic membrane that is free of chorion. A fluid component may be a fluid having a concentration of stem cells, such as amniotic stem cells, and/or micronized amniotic membrane particles. A preferred fluid component includes micronized amniotic membrane particles dispersed in an amniotic stem cell concentrated fluid. An amniotic stem cell concentrated fluid has at least 0.1 x 10 6  amniotic stem cells per milliliter of fluid or composition, A therapeutic composite may be used to treat any number of heart related conditions through topical application, injection or through introduction intravenously. A matrix component may be located on a treatment location and a fluid component may be subsequently introduced to the matrix component.
The invention relates to an aspirin-Arg-Gly-Asp-Val conjugate, synthesis, a nano structure, and an application thereof as a drug carrying system. The invention discloses a novel aspirin-Arg-Gly-Asp-Val (A-RGDV) conjugate, and also discloses a preparation method and an application thereof as an antithrombotic agent. The A-RGDV is characterized in that in the blood the A-RGDV can be selectively transferred as nano particles, when the A-RGDV nano particles arrive at the thrombus forming parts, the A-RGDV reacts with the GPIIb/IIIa receptors on the platelet surfaces, and thus aspirin is released during the process. So the A-RGDV can be used as a target drug delivery system for aspirin. A-RGDV has a strong antithrombotic activity, and has a good clinical application prospect. The structural formula of A-RGDV is represented in the description.
beta-Lactams of formula (I) and their esters and salts are new. In the formula R is 1-6C alkyl, or when A is O also H. A is O or OCO. R is H, acetoxy or SHet. Het is 1,2,3-triazol-5-yl, 1-methyl-tetrazol-5-yl, 1,3,4-thiadiazol-2-yl or 2-methyl-1,3,4-thiadiazol-5-yl. n is 0-8). (I) are antibacterials effective against Gram negative and positive species (esp. against Staph. aureus when given orally) and also intermediates for other pharmaceuticals. In an example 6-(2-D-amino-p-ethoxycarbonyloxyphenyl-acetamido) penicillanic acid was prepd. from amoxycillin by reacting first with ethyl acetoacetate and then with ethyl chloroformate.
First-line managers participate in a 3 hour lectur including a brief overview about worker health, occupational stress and the mismatch model and self-efficacy. Thereafter, they provide care-as-usual to employees at risk of future sick leave due to common mental disorders.
Bagaza virus (BAGV; Orthoflavivirus bagazaense) is an emerging vector-borne flavivirus affecting avian species with severe implications for animal health, and whose zoonotic potential has also been suggested. The aim of the present study was to monitor the epidemic outbreak of BAGV in wild birds from Spain in 2021. BAGV cases were confirmed in game bird species, including red-legged partridges (Alectoris rufa) and common pheasants (Phasianus colchicus) from 24 hunting areas. Suspected cases (clinical signs and/or mortality compatible with BAGV infection but without molecular confirmation) were also detected in 11 additional hunting areas. The outbreaks showed a seasonality mainly restricted to July and August. Estimated morbidity [25.8 % (95 %CI: 11.3-40.3) in partridges and 8.7 % (95 %CI: 0.0-18.0) in pheasants] and mortality rates [27.3 % (95 %CI: 12.5-42.1) in partridges and 13.0 % (95 %CI: 1.9-24.1) in pheasants] were found in the affected hunting areas. In addition, 215 non-game birds belonging to 46 different species were sampled by passive surveillance upon admittance to rehabilitation centres during 2021. BAGV infection was detected for the first time in green woodpecker (Picus viridis), spoonbill (Platalea leucorodia), white stork (Ciconia ciconia) and cynereous vulture (Aegypius monachus), expanding the host range of this emerging pathogen. In contrast to other species, game birds showed distinct BAGV related lesions, primarily myocarditis and encephalitis in addition to inflammatory infiltrates and necrosis in the liver and kidney. Molecular analyses revealed a homology of 97.4-98.0 % and 92.5-92.7 % between the BAGV sequences obtained in the present study (492 bp) and those isolated in 2010 and 2019 in southern Spain, respectively. These results allow to hypothesise about the likely silent and endemic circulation of BAGV since 2010 in this European region, although repeated virus reintroduction from neighbouring territories cannot be ruled out. Our findings evidence the sanitary, ecological and conservation implications of the re-emerged BAGV for wild birds, also emphasising the need to increase surveillance for monitoring and early detection of flavivirus dynamics in high-risk areas.
The kidney is vulnerable to ischemia and reperfusion (I/R) injury that can be fatal after major surgery. Currently, there are no effective treatments for I/R-induced kidney injury. Trimethylamine N-oxide (TMAO) is a gut-derived metabolite linked to many diseases, but its role in I/R-induced kidney injury remains unclear. Here, our clinical data reveals an association between preoperative systemic TMAO levels and postoperative kidney injury in patients after post-cardiopulmonary bypass surgery. By genetic deletion of TMAO-producing enzyme flavin-containing monooxygenase 3 (FMO3) and dietary supplementation of choline to modulate TMAO levels, we found that TMAO aggravated acute kidney injury through the triggering of endoplasmic reticulum (ER) stress and worsened subsequent renal fibrosis through TGFβ/Smad signaling activation. Together, our study underscores the negative role of TMAO in I/R-induced kidney injury and highlights the therapeutic potential through the modulation of TMAO levels by targeting FMO3, thereby mitigating acute kidney injury and preventing subsequent renal fibrosis.
Subjects that had worn contacts for at least two weeks without incident were selected. A baseline HRT was performed.Trial contacts lenses were soaked in Optifree Replenish contact solution for 10 hours. After 10 hours of the lenses soaking in Optifree Replenish the subject returned. The contacts were inserted onto the patients eyes. The patient wore contacts the for two hours. After two hours the contacts were removed. An HRT both with and without sodium fluorescein was performed immediately after removing the contact lenses.The HRT scans were analyzed for dendritic cell migration, basal cell epithelial density and nerve density and tortuosity.
The first method; There is no application in maintaining the drain opening, but if there are necessary medical indications such as clot formation, blood accumulation in the drainage connections, lack of drainage, this group is intervened by milking method. In our study, this group will be taken as a control group, there will be a situation that requires intervention in the first 6 hours, and if the milking method is used, it will be excluded from the sample.
The invention relates to a medicinal liquor for treating continuous hiccup. The medicinal liquor comprises Prsimmon Calyx, Syzygium aromaticum, realgar, Zanthoxylum bungeanum, ginger and Kaoliang spirit. A preparation method of the medicinal liquor for treating continuous hiccup comprises the following steps: adding medicines Prsimmon Calyx, Syzygium aromaticum, realgar, Zanthoxylum bungeanum and ginger into a container provided with Kaoliang spirit according to weight parts, and sealing the container, wherein a ratio of the medicines to the Kaoliang spirit makes the medicines be immersed in the Kaoliang spirit; and immersing the medicines in the Kaoliang spirit for at least 20-30d to obtain the medicinal liquor for treating continuous hiccup. When the medicinal liquor is needed, 100mL of the medicinal liquor is taken and is stewed out of water, and obtained steam is sniffed by noses to treat the continuous hiccup. Hiccup of mild patients is treated after the medicinal liquor is used once; and patients frequently suffering from the continuous hiccup can be cured after the medicinal liquor is used 3-7 times generally. The medicinal liquor has the characteristics of simple treatment method, effective treatment of the continuous hiccup, simple preparation method, short treatment course, fast effectiveness, and easy acceptance by patients.
Evaluating fluid responsiveness with dynamic parameters is recommended for fluid management. However, in hemodynamically stable patients who are breathing spontaneously, accurately measuring stroke volume variation via echocardiography and passive leg raising is challenging due to subtle SV changes. This study aimed to identify normal SV changes in healthy volunteers and evaluate the precision of hemodynamic parameters in screening mild hypovolemia in patients. This prospective, repeated-measures, cross-sectional study screened 269 subjects via echocardiography. Initially, 45 healthy volunteers underwent a fluid challenge test, the outcomes of which served as criteria to screen 215 ICU patients. Among these patients, 53 underwent additional fluid challenge testing. Hemodynamic parameters, including medians of maximum velocity time integrals (VTImaxs), peak velocity of VTImax (PV), internal jugular vein diameters (IJVD), and area (IJVA) were repeatedly measured first at a 60° upper body elevation (UBE), second in a supine position, third at UBE, fourth in a supine position, and lastly in a supine position after fluid loading. The hemodynamic responses to the position changes were compared between 83 fluid non-responders and 15 fluid responders. Fluid responsiveness was defined as fluid-induced medians' change of VTImaxs (fluid-induced median VTImax change) ≥ 10%. None of the healthy volunteers showed the mean value of repeatedly measured medians of VTImaxs ≥ 7%, following either UBE position (UBE-induced median VTImax change) or fluid loading (fluid-induced median VTImax change). UBE-induced median VTImax and PV changes were significantly correlated with fluid responsiveness (p < 0.001, AUC 0.959; p < 0.001, AUC 0.804). The significant correlations were demonstrated via multivariable analysis using binary logistic regression (p = 0.001, OR 90.1) and the correlation coefficient (R2 = 0.793) using linear regression analysis. UBE-induced median VTImax changes (≥ 11.8% and 7.98%) predicted fluid-induced median VTImax changes ≥ 10% and 7% (AUC 0.959 and 0.939). The collapsibility and variation of IJVD and IJVA showed no significant correlation. An increase in the mean value of medians of repeatedly measured VTImaxs transitioning from an UBE to a supine position, effectively screened mild hypovolemia and demonstrated a significant correlation with fluid responsiveness in spontaneously breathing patients maintaining hemodynamic stability.
Rituximab (375 mg/m2) will be given as a single intravenous infusion after remission. The prednisolone at a dose of 2 mg/kg per day (maximum 60 mg in single or divided doses) for 6 weeks, followed by 1.5 mg/kg (maximum 40 mg) as a single morning dose on alternate days for the next 6 weeks; therapy is then discontinued.
<P>PROBLEM TO BE SOLVED: To provide a naturally originated hypotensive action-having medicine or food composition which is safe and little requires worries against side effects and the like, even when administered for a long period.  <P>SOLUTION: This hypotensive action-having composition is characterized by containing silk protein obtained by removing sericin forming the outer layer portion of silk from the silk, especially a fibroin hydrolysate capable of being well absorbed in the bodies. The hypotensive action-having composition, food or medicine preferably further contains mulberry leaves, especially mulberry leaf powder, mulberry leaf extract and mulberry leaf extract powder, in an amount of 0.5 to 50 pts. wt. (converted into the original galenical) per pt. wt. of the silk protein.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
PROBLEM TO BE SOLVED: To obtain the subject medicament by including a specific dimethoxyindolecarboxylic acid and/or the like. SOLUTION: This medicament is obtained by including pref. 0.3-30 wt.% of a compound of the formula [R1 and R2 are each a (substituted) 1-6C alkyl, 7-12C aralkyl or the like] (pref. 4,6-dimethoxyindole-2-carboxylic acid or the like), its acylated modification and/or physiologically acceptable salt(s) thereof, singly or as a mixture. The compound of the formula is used in a composition used pref. as a cosmetic, wherein a physiologically acceptable medium is contained in the composition in the form of a lotion, gel, emulsion or the like in an amount enough to afford the composition through formulating a surfactant, thickening agent or gelatinizer, makeup agent, antiseptic, and acidifier or basifier.
Administered by corneal injection surgery. Dosage form:injection solution. Dose:200uL. Frequency of administration: one time injection.
Devices and methods relate to inducing or promoting hemostasis. The hemostasis device may include a support layer having a first surface and an opposing second surface. The device may include a layer, the layer disposed on the first surface. The layer may include a target surface configured to contact a target site. The layer may include a monolayer of about 100% graphene or may include laser-reduced graphene oxide. The device may include a sensor configured to measure a level of hemostasis of the target site. The methods relate to a method of manufacturing a hemostatic device including a monolayer of graphene or a layer of laser-reduced graphene oxide.
General: As with other anti-infectives, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. Ofloxacin should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity reaction. 

The systemic administration of quinolones, including ofloxacin, has led to lesions or erosions of the cartilage in weight-bearing joints and other signs of arthropathy in immature animals of various species. Ofloxacin, administered systemically at 10 mg/kg/day in young dogs (equivalent to 110 times the maximum recommended daily adult ophthalmic dose) has been associated with these types of effects. 

Information for Patients: Avoid contaminating the applicator tip with material from the eye, fingers or other source. 

Systemic quinolones, including ofloxacin, have been associated with hypersensitivity reactions, even following a single dose. Discontinue use immediately and contact your physician at the first sign of a rash or allergic reaction. 

Drug Interactions: Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly. 

Carcinogenesis, Mutagenesis, Impairment of Fertility: Long term studies to determine the carcinogenic potential of ofloxacin have not been conducted. 

Ofloxacin was not mutagenic in the Ames test, in vitro and in vivo cytogenic assay, sister chromatid exchange assay (Chinese hamster and human cell lines), unscheduled DNA synthesis (UDS) assay using human fibroblasts, the dominant lethal assay, or mouse micronucleus assay. Ofloxacin was positive in the UDS test using rat hepatocyte, and in the mouse lymphoma assay. 

In fertility studies in rats, ofloxacin did not affect male or female fertility or morphological or reproductive performance at oral dosing up to 360 mg/kg/day (equivalent to 4000 times the maximum recommended daily ophthalmic dose).
Patients receive arginine PO QID. Treatment continues for up to 3 months in the absence of disease progression or unacceptable toxicity.
Participants assigned to this condition will be asked to wear a pedometer daily and scheduled for weekly meetings over for the next 12 weeks. The meeting duration and structure will be similar to that in the standard treatment condition including the handouts, with one exception. Participants in this condition will earn tangible reinforcement in the form of prizes for walking the target number of steps per day.
Study meals were administered in commonly consumed serving sizes (6 oz beef \[Philly-Gourmet Beef Patties\]) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
The dose is 1.4 mg/m2 for 5 minutes intravenously. If necessary, the dose may be diluted in up to 100 mL of saline solution prior to intravenous administration. Gemcitabine doses 1000 mg/m2 intravenously for 30 minutes. After completion of the eribulin injection, intravenously inject gemcitabine. One cycle is 3 weeks, and the treatment is carried out on the 1st day and the 8th day for each cycle.
This study will investigate the specific reward and cognitive mechanisms that mediate the effects of LDX on eating in participants with sub-clinical binge-eating disorder symptoms. A sub-clinical sample will be recruited in line with the Research Domain Criteria Initiative established by the US National Institute of Mental Health which encourages research on dimensions of observable behaviour rather than a categorical, symptom-based approach to the study of mental health. The tendency towards binge-like eating will be modelled using an eating in the absence of hunger paradigm in which participants consume a pasta meal and are then offered the opportunity to consume as many palatable cookies as they like. Reward processes will be assessed by measuring neural and behavioural responses to palatable food pictures using functional Magnetic Resonance Imaging (fMRI). Responses to emotional stimuli will be assessed using the P1vital® Oxford Emotional Test Battery. Impulsive responding will be assessed using the delay discounting task and the stop signal task. Attentional processing will be assessed using the sustained performance task and working memory will be assessed with the n-back task.
Parkin (PARK2) deficiency is frequently observed in various cancers and potentially promotes tumor progression. Here, we showed that Parkin expression is downregulated in liver cancer tissues, which correlates with poor patient survival. Parkin deficiency in liver cancer cells promotes migration and metastasis as well as changes in EMT and metastasis markers. A negative correlation exists between TMEFF1 and Parkin expression in liver cancer cells and tumor tissues. Parkin deficiency leads to upregulation of TMEFF1 which promotes migration and metastasis. TMEFF1 transcription is activated by Parkin-induced endogenous TGF-β production and subsequent phosphorylation of Smad2/3 and its binding to TMEFF1 promotor. TGF-β inhibitor and TMEFF1 knockdown can reverse shParkin-induced cell migration and changes of EMT markers. Parkin interacts with and promotes the ubiquitin-dependent degradation of HIF-1α/HIF-1β and p53, which accounts for the suppression of TGF-β production. Our data have revealed that Parkin deficiency in cancer leads to the activation of the TGF-β/Smad2/3 pathway, resulting in the expression of TMEFF1 which promotes cell migration, EMT, and metastasis in liver cancer cells.
BACKGROUND: In recent years, the incidence of Endometrial cancer (EC) has been on the rise due to high-fat, high-calorie diets and low-exercise lifestyles. However, the relationships between metabolic disorders and the progression of EC remain uncertain. The purpose of our study was to explore the potential association between obesity, hypertension, hyperglycemia and clinicopathologic characteristics in EC patients.
METHODS: In categorical variables, Chi-square tests were used to calculate P values. Univariate logistic regression and multivariate logistic regression were used to identify the risk factors of myometrial invasion>1/2 and lymph node metastasis. Overall survival (OS) was estimated using the Kaplan-Meier method.
RESULTS: The study included 406 individuals with EC, 62.6% had type I and 37.4% had type II. Hypertension was seen in 132 (32.5%), hyperglycemia in 75 (18.5%), and overweight or obesity in 217 (53.4%). Hypertension, hyperglycemia, and obesity are strongly associated with the clinicopathologic features of EC. Multivariate logistic regression revealed that hyperglycemia (OR=2.439,95% CI: 1.025-5.804, P = 0.044) was a risk factor for myometrial invasion depth >1/2 in patients with type I EC, and hypertension (OR=32.124,95% CI: 3.287-313.992, P = 0.003) was a risk factor for lymph node metastasis in patients with type I EC. Survival analysis found that hyperglycemia (P < 0.001) and hypertension (P = 0.002) were associated with OS in type I EC. Neither hyperglycemia, hypertension, nor obesity were associated with the prognosis in type II EC.
CONCLUSION: Hyperglycemia was a risk factor for myometrial invasion depth >1/2 in patients with type I EC and hypertension was a risk factor for lymph node metastasis in patients with type I EC. Hypertension and hyperglycemia were associated with poor prognosis in patients with type I EC.
OBJECTIVE: Ovarian cancer screening is a difficult problem due to the anatomy of the ovaries. Only histology allows a definite diagnosis. Our objective was to study the contribution of the Adnex score in the histological characterization of adnexal images for adequate management.
METHODS: It was a retrospective, mono-center, descriptive and analytical. Sixty-five patients were included, those operated for an ovarian cyst and meeting the Adnex criteria: clinical, ultrasound and laboratory.
RESULTS: The mean age of the patients was 38.6 years. They were nulliparous in 43 % of cases, and only four had a history of operation on ovarian cyst. Abdominal pelvic pain was the most frequent reason for consultation in 48 % of cases. An abdominopelvic mass was found on abdominal examination in 11 % of cases. Pelvic ultrasound made it possible to objectify the presence of an ovarian mass in all cases, with an average size of 79.66mm and a reassuring appearance in 66 % of cases. The calculation of the Adnex score was done in all patients preoperatively, for a 10 % cut-off, the model showed an 86 % chance of benignity for tumors proven to be histologically benign. The main route of entry was laparoscopy, in 61 % of cases. The treatment was in most cases conservative consisting essentially of a cystectomy.
CONCLUSION: The Adnex score discriminated well between benign and malignant masses, allowing for a better diagnosis preoperatively. It thus deserves its applicability in the clinical setting.
Six patients will be enrolled in the Phase 1 safety cohort. Patients will have an IR guided biopsy and FNA. Up to four core biopsies and FNAs at one site will be performed prior to intratumoral (IT) administration of Poly-ICLC. Pleural fluid will be collected for research analysis if available. Poly-ICLC will be injected in 2 locations within the pleura. Patients will undergo surgery 21±7 days after the biopsy and Poly-ICLC intratumoral (IT) injection. The type of surgery that will be performed is at the discretion of the thoracic surgeon and per the standard of care. This includes pleurectomy/decortication or extrapleural pneumonectomy. Patients will be evaluated per the standard of care post-operatively. On day 7±4 days a final toxicity assessment, physical exam and research blood will be collected. All post-operative care and monitoring thereafter is as per standard of care.